Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 41 min ago
Peer-reviewedCC BYFrontiers in oncology

Selinexor enhances temozolomide efficacy in glioblastoma through modulation of multiple resistance-associated mechanisms

  • Beyza Ozturk1
  • Asuman Celebi2
  • Deniz Kilic3
  • Turker Kilic4
  • Timucin Avsar2
4 affiliations
  1. 1Neurooncology Laboratory, Neuroscience PhD Program, Graduate School, Bahçeşehir University , ,
  2. 2Department of Medical Biology, Faculty of Medicine, Bahçeşehir University , ,
  3. 3Department of Neurosurgery, School of Medicine, Bahçeşehir University, Goztepe Medical Park Hospital , ,
  4. 4Department of Neurosurgery, School of Medicine, Istinye University, Goztepe Medical Park Hospital , ,
Read full textPDFCite

Related

  1. Reduced DDB2 Expression Is Associated with Temozolomide Resistance in Glioblastoma Cells
    Inés Grávalos-Cano, Teresa Morales-Ruiz, Rafael R. Ariza +2
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textHuman geneticsCrossrefEurope PMC
  2. Tumor Treating Fields Enhance Temozolomide-Associated Growth Suppression in Glioblastoma Cells and Patient-Derived Organoids Through Cell-Cycle Blockade, Apoptosis, and SMAD-Associated Signaling.
    Haiping Zhu, Yingbo Hou, Xuetao Li +14
    CNS neuroscience & therapeuticsPeer-reviewedCC BYFull textHuman geneticsEurope PMC
  3. TMBIM4 acts as a novel prognostic biomarker for glioblastoma and is associated with temozolomide chemoresistance.
    Jianeng Pu, Tianhua Li, Shuai Zhou +1
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  4. Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial
    Dorota Goplen, Mohummad Aminur Rahman, Jorunn Brekke +8
    Biomarker ResearchPeer-reviewedCC BY 4.0Full textHuman geneticsPMC
  5. Temozolomide-associated inflammatory-repair remodeling in recurrent glioblastoma exposes a ROCK-linked therapeutic vulnerability
    R. Chojak, U. H. Faisal, P. U. Kumthekar +24
    bioRxivPreprintCC BYFull textOncologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{ozturk2026selinexor,
  title = {{Selinexor enhances temozolomide efficacy in glioblastoma through modulation of multiple resistance-associated mechanisms}},
  author = {Beyza Ozturk and Asuman Celebi and Deniz Kilic and Turker Kilic and Timucin Avsar},
  journal = {Frontiers in oncology},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13655233},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Selinexor enhances temozolomide efficacy in glioblastoma through modulation of multiple resistance-associated mechanisms
AU  - Beyza Ozturk
AU  - Asuman Celebi
AU  - Deniz Kilic
AU  - Turker Kilic
AU  - Timucin Avsar
PY  - 2026
DA  - 2026/10/16
JO  - Frontiers in oncology
UR  - https://europepmc.org/article/PMC/PMC13655233
SN  - 2234-943X
ER  -